The Role of Social Media in Managaing Chronic Diseases

The Role of Social Media in Managaing Chronic Diseases Focus on Diabetes and ObesityIn an "Open letter to NPR about Diabetes Social Media piece,"...

Sanofi US Diabetes Team Wins 3rd Annual Pharmaguy Social Media Pioneer Award

PharmaGuy (aka John Mack) presented the coveted bright yellow Hawaiian shirt/Pharmaguy Social Media Pioneer Award to Dennis Urbaniak, VP, Joan Mikardos, Senior Director, and Laura Kolodjeski, Senior Manager, Patient Solutions, at Sanofi US Diabetes. The award was made at the 6th Annual Digital Pharma East conference in Philadelphia on October 17, 2012. Accepting the award on behalf of the winners -- who could not make it in person -- was Wendy Blackburn of Intouch Solutions.

Multichannel Marketing: Easy to Brag About, but Difficult to Do

Multichannel pharma marketing is conceptually relatively simple to understand, but incredibly difficult in practice, says Len Starnes, former Head of Digital Marketing & Sales, General Medicine at Bayer Schering Pharma. That said, multichannel is not a transient phenomenon, it's here to stay. Starnes hosted a survey on LinkedIn to answer the question: When will pharma marketing become de facto multichannel marketing in future?

Supporting Patients via Twitter and Beyond

Although nearly two-thirds of respondents to a 2009/2010 Pharma Marketing News survey thought that using Twitter for patient support activities would be somewhat or very effective, relatively few pharmaceutical companies are doing this on a regular basis. From time to time, however, it does happen. Boehringer Ingelheim Shows How It's Done

Who Owns Your Social Media?

Twitter's new rules change the playing field for third party developers, establish caps on number of users, and shift guidelines to requirements across four categories of businesses. Will the new rules ruin the spirit of social media and are they bad for healthcare?

Pharma Marketing News Vol. 11, No. 11: 27 December 2012

Welcome to Volume 11, Issue #11 (27 December 2012) of Pharma Marketing News.

Pfizer Throws In the Lipitor Marketing Towel. Meanwhile AstraZeneca Promotes Crestor on Its Corporate...

Despite Pfizer's heroic and unprecedented effort to maintain Lipitor's market share after expiry last November and after spending more than $87 million promoting the medicine, the world's biggest drug company is quietly giving up on its once-great cash cow for good because more generic versions will soon be going on sale. Meanwhile, AstraZeneca promoted Crestor on its corporate blog. It's unusual for a pharmaceutical company to mention a product by brand name on its corporate blog. It's even more unusual to mention BOTH the product AND its indication -- because that would be promotion regulated by the FDA. But AstraZeneca has done just that on its 'AZ Health Connections' corporate blog. Why now? Can it be a purely opportunistic cheap shot?

Mobile Regulatory Fears: PhRMA Raises an Alarm

In a blog post provocatively titled 'An App for That, But For How Much Longer?', PhRMA's Kate Connors agreed with a Washington Times op-ed piece that suggested the FDA will soon require apps such as medication prescription renewal reminders and blood glucose level tracking functions to be regulated as medical devices. The op-ed author, Joel White, executive director of the Health IT Now Coalition, suggests that this effort would lead to increased costs as well as constraints on user access to these apps, which 'may cause developers to move on to other, less burdensome endeavors.' 'In the end, this could hinder the way that patients can actively improve their own care,' said Conners. Is this fear warranted? Are there apps that SHOULD be regulated by the FDA? Read this article and find out.

The iPad in the Doctor’s Office

The Apple iPad has also become a

Are Some DTC Print Ads Too Educational and/or Persuasive?

FDA Plans to Do Two Studies to Find Out
- Advertisement -